SHR-1826 + SHR-9839

**SHR-1826 + SHR-9839** is a combination under clinical investigation for the treatment of advanced malignant solid tumors, notably including non-small cell lung cancer. SHR-1826 is an antibody-drug conjugate (ADC) targeting c-Met (hepatocyte growth factor receptor), designed to deliver a cytotoxic payload specifically to cancer cells expressing c-Met, and SHR-9839 is a bispecific antibody targeting EGFR (epidermal growth factor receptor) and c-Met, aiming to inhibit tumor signaling pathways associated with proliferation and resistance. Both agents are being evaluated for safety, tolerability, and anti-tumor efficacy, primarily in phase 1/2 clinical trials. The combination exploits dual targeting of c-Met and EGFR to address tumor heterogeneity and resistance mechanisms. Both agents are developed by Suzhou Suncadia Biopharmaceuticals and Shanghai Hengrui Pharmaceutical. The primary indication is advanced solid tumors, with a major focus on non-small cell lung cancer[1][2][4][7][9].